ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on March 1, 2024 (the “Grant Date”), ORIC granted a total of 3,600 non-qualified…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks